Mikirduit US (Page 4)

Stock Insight

Sana Biotechnology Could Be a Multibagger—or a Major Loss. Here’s the Risk-Reward Setup

Sana Biotechnology offers high-risk, high-reward biotech exposure, with SC451 and SG293 driving the upside while cash burn and dilution remain major risks.

Index & ETF Watch

U.S. Stocks Face Pressure as Fed Rate-Hike Expectations Build. Here Are ETFs Investors Can Accumulate

Fed rate-hike expectations are pressuring U.S. stocks, but the pullback may create opportunities to gradually accumulate Nasdaq-100, S&P 500 and broad-market ETFs.

Stock Insight

Oil Is Back at $100. Which Energy Stocks Are Worth Watching—and Which Are Too Expensive?

Brent is back near $100 a barrel, boosting U.S. energy stocks. We compare EOG, Chevron and Exxon to see which names offer the best risk-reward—and why this may not be the best time to chase oil stocks.

Stock Insight

Circle Is Paying $400 Million for Tazapay. Why CRCL Stock Fell—and What the Deal Could Mean

Circle’s $400 million all-stock acquisition of Tazapay could accelerate its push into global payments, but dilution, regulatory risk and a still-premium CRCL valuation remain key concerns.

Stock Insight

WaFd’s EverBank Merger Could Boost 2027 EPS by 29%. Here’s What WAFD Investors Need to Know

WaFd’s merger with EverBank will heavily dilute existing shareholders, but management expects the larger bank to deliver 29% EPS accretion in 2027 and substantial cost synergies.

Stock Insight

Boston Scientific Could Cut Its 2026 Outlook for a Third Time. Is BSX Stock Finally Cheap?

Boston Scientific may cut its 2026 outlook for a third time after a cyberattack disrupted operations, but BSX’s steep selloff and lower valuation could be creating an opportunity.

Market & Macro

Oil Is Closing In on $100 a Barrel. Here’s What Investors Can Do Now

Oil prices are closing in on $100 a barrel as Middle East tensions and tighter supply lift crude, creating upside for energy stocks but raising fresh inflation and Fed risks.

Earnings Digest

Virco’s Profit Slumps, but the Stock Rallies. Here’s What Investors Should Watch Next

Virco shares rallied despite a sharp drop in first-half profit as quarterly results beat expectations, backlog improved, and investors looked ahead to a potential recovery in 2027.

Latest

Sana Biotechnology Could Be a Multibagger—or a Major Loss. Here’s the Risk-Reward Setup

U.S. Stocks Face Pressure as Fed Rate-Hike Expectations Build. Here Are ETFs Investors Can Accumulate

Oil Is Back at $100. Which Energy Stocks Are Worth Watching—and Which Are Too Expensive?

Circle Is Paying $400 Million for Tazapay. Why CRCL Stock Fell—and What the Deal Could Mean

WaFd’s EverBank Merger Could Boost 2027 EPS by 29%. Here’s What WAFD Investors Need to Know

Boston Scientific Could Cut Its 2026 Outlook for a Third Time. Is BSX Stock Finally Cheap?

Oil Is Closing In on $100 a Barrel. Here’s What Investors Can Do Now

Virco’s Profit Slumps, but the Stock Rallies. Here’s What Investors Should Watch Next